GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » POINT Biopharma Global Inc (NAS:PNT) » Definitions » Total Stockholders Equity

POINT Biopharma Global (POINT Biopharma Global) Total Stockholders Equity : $424.2 Mil (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is POINT Biopharma Global Total Stockholders Equity?

POINT Biopharma Global's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $424.2 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. POINT Biopharma Global's Book Value per Share for the quarter that ended in Sep. 2023 was $4.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. POINT Biopharma Global's Debt-to-Equity for the quarter that ended in Sep. 2023 was 0.03.

POINT Biopharma Global Total Stockholders Equity Historical Data

The historical data trend for POINT Biopharma Global's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

POINT Biopharma Global Total Stockholders Equity Chart

POINT Biopharma Global Annual Data
Trend Dec20 Dec21 Dec22
Total Stockholders Equity
13.48 255.21 486.95

POINT Biopharma Global Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 309.08 486.95 471.78 447.45 424.19

POINT Biopharma Global  (NAS:PNT) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

POINT Biopharma Global's Book Value per Share for the quarter that ended in Sep. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(424.192-0)/105.766
=4.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

POINT Biopharma Global's Debt-to-Equity for the quarter that ended in Sep. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.927 + 8.736) / 424.192
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

POINT Biopharma Global Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of POINT Biopharma Global's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

POINT Biopharma Global (POINT Biopharma Global) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » POINT Biopharma Global Inc (NAS:PNT) » Definitions » Total Stockholders Equity
Comparable Companies
CPRX SMMT PTCT RYTM RYZB HRMY MRUS ABCL AGIO SWTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
4850 West 78th Street, Indianapolis, IN, USA, 46268
Website
https://www.pointbiopharma.com
POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.
Executives
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Joe A. Mccann director, officer: Chief Executive Officer 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Rajesh Malik director 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Gerald L. Hogue director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
David Charles Lubner director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472